Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF).
Even though oral tongue cancer is generally diagnosed at an early stage, the prognosis is poor due to frequent recurrence. Therefore, it is important to identify factors predictive of recurrence and to treat aggressively those patients with a high probability of recurrence. The relationship between angiogenesis and recurrence in tongue cancer has been widely investigated but no consensus has been reached. Mutant-type p53 and VEGF are known to be related to angiogenesis, and maspin is a potent angiogenic inhibitor but its role in tongue cancer has scarcely been examined. We observed the expression of maspin, mutant-type p53 and VEGF by immunohistochemistry in 33 patients with stages I and II oral tongue cancer. And the relationships between maspin, mutant-type p53, VEGF expression and recurrence were analyzed. Maspin and VEGF displayed a cytoplasmic staining pattern and mutant-type p53 a nuclear pattern. None of expression of maspin, mutant-type p53, and VEGF was significantly correlated with tumor recurrence (p=0.34, 0.56, and 0.33, respectively) and survival. Maspin expression was negatively correlated with both mutant-type p53 expression (p=0.02), and VEGF expression (p=0.01). There was no correlation between age, sex, clinical staging, and recurrence. In conclusion, the expression of maspin is not related to recurrence of early stage oral tongue cancer. It is inversely correlated with that of mutant-type p53 and of VEGF, suggesting that the maspin gene is a mutant-type p53 target in vivo and may contribute to regulate VEGF expression.
Cho
Jae Hoon
JH
Department of Otorhinolaryngology, Head and Neck Surgery, College of Medicine, Kon-Kuk University, Seoul, Republic of Korea.
Kim
Hyung-Seok
HS
Park
Chang-Soo
CS
Kim
Jin Kook
JK
Jung
Kwang-Yoon
KY
Shin
Bong-Kyoung
BK
Kim
Han-Kyum
HK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000737:chemistry / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D015843:Serpins / Q000032:analysis*; D014062:Tongue Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis*
C085344:SERPIN-B5; D015843:Serpins; D016159:Tumor Suppressor Protein p53; D042461:Vascular Endothelial Growth Factor A